早期胸腺瘤微创胸腺切除术的应用与R0切除率分析
微创使用率从21.0%升至40.2%,R0切除率83.1%对79%,多因素分析显示R0切除与手术方式无关,微创住院时间更短。
要点
- 微创胸腺切除术用于早期胸腺瘤的比例在研究期间显著上升。
- 微创与开放手术的R0切除率无显著差异。
- II期肿瘤和WHO B3型组织学与不完全切除风险相关。
核心结论
- 微创胸腺切除术用于早期胸腺瘤切除日益增多,且与开放手术相比不降低R0切除率。
主要发现
- 微创手术占31.3%(其中机器人59.7%,胸腔镜40.3%),使用率从21.0%增至40.2%(趋势检验p<0.001)。
- 微创R0切除率83.1%(I期86.6%,II期72.7%),开放R0切除率79%(I期85.5%,II期65.8%)。
- 多因素分析中,不完全切除(R1/2)与II期肿瘤(OR 2.51)和WHO B3型组织学(OR 3.66)相关。
- R0切除与手术方式无关(p=0.17),且不随肿瘤大小变化(趋势检验p=0.90)。
- 30天和90天死亡率分别为0%和0.5%;微创手术住院时间较开放手术缩短1.03天(95%CI -1.68至-0.38)。
关键数值与推荐
- 微创胸腺切除术使用率从21.0%上升至40.2%(趋势检验p<0.001)。
- 微创R0切除率83.1%,开放79%;R0切除与手术方式无关(p=0.17)。
- II期肿瘤不完全切除OR 2.51,WHO B3型组织学OR 3.66。
- 微创手术住院时间较开放手术缩短1.03天(95%CI -1.68至-0.38)。
临床怎么用
- 早期胸腺瘤可考虑微创胸腺切除术,其R0切除率与开放手术相当且住院时间更短。
- 对II期肿瘤和WHO B3型组织学患者应警惕不完全切除风险。
局限性
- 回顾性研究设计,需进一步探究所有胸腺切除术中R0切除率相对较低的原因。
- 需要长期结局数据以更好定义微创胸腺切除术的肿瘤学有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimally invasive thymectomy (MIT) has demonstrated improved short-term outcomes compared with open thymectomy (OT). Although adoption of MIT for thymoma is increasing, oncologic outcomes have not been well characterized. METHODS: This was a retrospective cohort study of adult patients from the National Cancer Database who underwent MIT or OT for Masaoka stage I to II thymoma between 2010 and 2014. The primary outcome was R0 resection. Secondary outcomes included MIT use, perioperative mortality, and length of stay. RESULTS: Nine hundred forty-three patients from 395 hospitals underwent thymectomy for stage I to II thymoma. MIT was performed in 31.3% (59.7% robotic, 40.3% thoracoscopic). Over the study period MIT utilization increased from 21.0% to 40.2% (trend test, p < 0.001). R0 resection was achieved in 83.1% of MITs (86.6% stage I, 72.7% stage II) and 79% of OTs (85.5% stage I, 65.8% stage II). In multivariable analyses, the likelihood of incomplete resection (R1/2) was associated with stage II tumors (odds ratio, 2.51) and World Health Organization B3 histology (odds ratio, 3.66). R0 resection was not associated with surgical approach (p = 0.17) and did not vary with tumor size (trend test, p = 0.90). Mortality rates at 30 and 90 days were 0% and 0.5%, respectively. MIT was associated with significantly shorter lengths of stay than OT (-1.03 days [95% confidence interval, -1.68 to -0.38]). CONCLUSIONS: The use of MIT for resection of early-stage thymoma is increasing and is not associated with lower rates of R0 resection than OT. Reasons for the relatively low rates of R0 resection among all thymectomies requires further investigation, and long-term outcomes data are needed to better define the oncologic effectiveness of MIT.
引用
- Burt BM, Nguyen D, Groth SS, et al. Utilization of Minimally Invasive Thymectomy and Margin-Negative Resection for Early-Stage Thymoma. Ann Thorac Surg. 2019. PMID: 30953650. doi:10.1016/j.athoracsur.2019.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。